Is Saroja Pharma In overvalued or undervalued?
As of May 29, 2025, Saroja Pharma is fairly valued with a PE Ratio of 14.91, significantly lower than peers like Sun Pharmaceutical (35.25), indicating it may be undervalued despite a year-to-date return of -36% compared to the Sensex's 6.23%.
As of 29 May 2025, Saroja Pharma In's valuation grade has moved from does not qualify to fair. The company appears to be fairly valued at this time. Key ratios include a PE Ratio of 14.91, an EV to EBITDA of 6.97, and a PEG Ratio of 0.87, which suggests a reasonable valuation relative to its growth prospects.In comparison to its peers, Saroja Pharma's PE Ratio is significantly lower than that of Sun Pharmaceutical Industries Ltd., which stands at 35.25, indicating that Saroja may be undervalued relative to this competitor. Other peers, such as Cipla Ltd. and Dr. Reddy's Laboratories Ltd., have PE Ratios of 22.99 and 19.49, respectively, further supporting the notion that Saroja Pharma is positioned attractively within its industry. Despite recent underperformance against the Sensex, with a year-to-date return of -36% compared to the Sensex's 6.23%, the company's current valuation metrics suggest it is not overvalued.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
